Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
1. Eli Lilly's shares dropped over 14%, signaling the largest loss in decades. 2. Orforglipron helped patients lose 12% body weight, below 15% expected. 3. Novo Nordisk shares rose after revealing better weight loss data. 4. CEO stated results were acceptable despite missing Wall Street's predictions. 5. Eli Lilly plans to file for regulatory approval of orforglipron by year-end.